Filing Analysis
Inogen Inc. announced the appointment of Andrew (Andy) Reding as Executive Vice President and Chief Operating Officer, effective July 6, 2026. The filing details his compensation package, including a $500,000 base salary and an equity award of 130,000 RSUs.
🚩 Red Flags
- None identified; this is a standard executive appointment filing.
📋 Key Facts
- Appointment of Andrew (Andy) Reding as EVP and COO, effective July 6, 2026.
- Annual base salary set at $500,000 with a 70% target annual performance bonus.
- Includes a $100,000 cash sign-on bonus (repayable if terminated for cause or resignation within two years).
- Equity award of 130,000 time-based Restricted Stock Units (RSUs) vesting over three years.
- Severance provisions include 12 months of salary/COBRA subsidy, increasing to 24 months in the event of a change of control.
Inogen Inc. reported the results of its June 5, 2026, annual meeting of stockholders. Key outcomes include the approval of an amended equity incentive plan and the election of Class III directors, though a proposal to declassify the board was not approved.
🚩 Red Flags
- Stockholders rejected the amendment to declassify the board, which may indicate a preference for maintaining the current staggered board structure or a lack of consensus on corporate governance changes.
📋 Key Facts
- Stockholders approved the Amended and Restated 2023 Equity Incentive Plan, increasing available common stock for issuance by 750,000 shares.
- Glenn Boehnlein and Mira Sahney were elected as Class III directors until the 2029 annual meeting.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- The advisory vote on executive compensation was approved.
- The proposal to declassify the Board of Directors was not approved.
- Meeting participation was approximately 76.28% of outstanding shares (20,844,941 shares represented).
Inogen Inc. reported its financial results for the first quarter ended March 31, 2026. The filing serves as a formal vehicle to furnish the quarterly earnings press release to the SEC.
📋 Key Facts
- Reporting financial results for the first quarter ended March 31, 2026.
- The report was filed on May 7, 2026.
- Jason Richardson, Executive Vice President and CFO, signed the filing.
- The information is furnished under Item 2.02 and is not deemed 'filed' for liability purposes.
Inogen Inc. entered into a cooperation agreement with activist investor Kent Lake Partners LP, resulting in the appointment of Vafa Jamali to the Board of Directors. The agreement includes customary standstill provisions and voting commitments from the investor group through early 2027.
🚩 Red Flags
- Presence of activist investor pressure (Kent Lake Partners) necessitating a formal cooperation agreement.
- Restrictive standstill provisions and a 4.99% ownership cap suggest a move to limit the activist's influence.
📋 Key Facts
- Cooperation Agreement signed on April 6, 2026, with Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter.
- Vafa Jamali appointed as a Class I director and member of the Audit and Compliance Committees, effective by June 15, 2026.
- Investor Parties are capped at a beneficial ownership of 4.99% of outstanding shares.
- The Investor Parties agreed to vote in accordance with Board recommendations, with exceptions for extraordinary transactions.
- Vafa Jamali previously served as CEO of ZimVie Inc. and Senior VP at Medtronic plc.
- Mr. Jamali will receive an initial RSU grant valued at $180,000 and annual cash fees totaling $60,000 for board and committee service.
Inogen Inc. has appointed Jason Richardson as Executive Vice President, Chief Financial Officer, and Treasurer, effective April 6, 2026, succeeding Michael Bourque. Mr. Richardson joins from Baxter International, where he served as CFO of the Health System and Technologies Segment.
📋 Key Facts
- Jason Richardson appointed as EVP, CFO, and Treasurer effective April 6, 2026.
- Richardson's compensation includes a $525,000 base salary, a 70% target performance bonus, and $100,000 in combined sign-on and retention bonuses.
- Equity inducement awards include 100,000 time-based RSUs and 100,000 performance-based RSUs (PSUs), with a maximum PSU payout of 150,000 shares.
- Outgoing CFO Michael Bourque will remain as a Senior Advisor through June 30, 2026, to assist with the transition.
- Richardson previously held senior finance roles at Baxter International and Hillrom.
Inogen Inc. reported its Q4 and full-year 2025 financial results and announced a new $30 million share repurchase program authorized by its Board of Directors.
📋 Key Facts
- Board of Directors approved a $30 million common stock repurchase program on February 20, 2026.
- The repurchase program is scheduled to expire on the earlier of December 31, 2027, or when the authorized amount is fully utilized.
- The company reported financial results for the fourth quarter and full year ended December 31, 2025, on February 24, 2026.
- The company's principal executive offices have relocated from Goleta, California, to Beverly, Massachusetts.
Inogen, Inc. issued a press release containing preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025.
📋 Key Facts
- Report date: January 12, 2026
- Reporting period: Q4 and Full Year ended December 31, 2025
- Nature of data: Preliminary and unaudited revenue results
- The information is subject to change upon completion of audited financial statements.
Inogen, Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 30, 2025.
📋 Key Facts
- Reporting date: November 5, 2025
- Period covered: Third Quarter ended September 30, 2025
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Inogen, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal cover sheet for the release of quarterly earnings data.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 7, 2025.
- The company furnished an earnings press release as Exhibit 99.1.
Inogen, Inc. announced the designation of two internal employees as Executive Officers effective July 28, 2025: Jennifer Yi Boyer (EVP, Enterprise Enablement and CHRO) and Mary Wright (Chief Accounting Officer). Both individuals are being elevated to Section 16 officer status due to increased responsibilities.
📋 Key Facts
- Jennifer Yi Boyer designated as Executive Officer and Section 16 Officer effective July 28, 2025; annual base salary of $430,000 with a 50% target bonus.
- Mary Wright appointed Chief Accounting Officer (CAO) and designated as Executive Officer/Section 16 Officer effective July 28, 2025; annual base salary of $312,000 with a 35% target bonus.
- Michael Bourque will continue to serve as the principal accounting and financial officer for SEC filings.
- Both appointments involve internal promotions/designations rather than external hires.
Inogen, Inc. reported the results of its annual meeting of stockholders held on May 14, 2025. Key outcomes included the approval of an amended equity incentive plan and the ratification of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Stockholders approved the adoption of the Amended and Restated 2023 Equity Incentive Plan.
- The amendment increases the number of shares available under the plan by an additional 750,000 shares.
- Kevin King, Mary Kay Ladone, and Kevin R.M. Smith were elected to serve as Class II directors until 2028.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Stockholders approved executive compensation on an advisory, non-binding basis.
- Quorum was met with approximately 77.87% of outstanding shares represented (20,937,688 shares).
Inogen, Inc. filed an 8-K to report its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Report date: May 7, 2025.
- The filing includes Exhibit 99.1 containing the press release of financial results.
Inogen, Inc. filed an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2024.
📋 Key Facts
- Reported date: February 25, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Inogen, Inc. announced the resignation of Director Thomas A. West and the simultaneous appointment of Mira Kirti Sahney to the Board, Nominating and Governance Committee, and Compliance Committee.
🚩 Red Flags
- None identified; resignation was explicitly stated as not being due to a disagreement.
📋 Key Facts
- Thomas A. West resigned from the Board, Compliance Committee, and Nominating and Governance Committee effective January 30, 2025.
- The company stated Mr. West's resignation was not due to any disagreement regarding operations, policies, or practices.
- Mira Kirti Sahney appointed as Class III director effective January 31, 2025.
- Ms. Sahney will serve on the Nominating and Governance Committee and Compliance Committee.
- Ms. Sahney received an initial award of 9,112 restricted stock units (RSUs) vesting on May 14, 2025.
- Annual cash compensation for Ms. Sahney: $45,000 for Board service and $5,000 each for the two committees ($65,000 total per year).
Inogen, Inc. entered into a strategic collaboration and a $27.2 million private placement with Yuwell (Hong Kong) Holdings Limited. The deal includes distribution agreements in the US, Europe, and Asia Pacific, alongside R&D collaboration.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of 2.6M new shares.
- Registration Rights Agreement allows the investor to force a registration statement, creating potential future selling pressure (overhang).
📋 Key Facts
- Entered into Strategic Collaboration Agreement with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (Yuwell) on January 25, 2025.
- Private placement of 2,626,425 shares at $10.36 per share, totaling approximately $27.2 million.
- Closing of the private placement is expected in Q1 2025.
- Registration Rights Agreement grants Investor rights to register resale after 180 days.
- Includes mutual distribution arrangements: Inogen distributes Yuwell products in US/Europe; Yuwell distributes Inogen products in Asia Pacific.
Inogen, Inc. issued a press release containing preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2024.
🚩 Red Flags
- Data is preliminary and unaudited, meaning final figures may vary
📋 Key Facts
- Reporting date: January 13, 2025
- Subject matter: Preliminary, unaudited revenue results for Q4 and Full Year 2024
- The financial data is subject to change upon completion of audited statements
- Results are furnished via Exhibit 99.1
Inogen, Inc. announced FDA 510(k) clearance for its Simeox 200 device, intended for airway clearance and bronchial drainage improvement. This regulatory milestone triggers a $13 million cash earnout payment to sellers under a previous Share Purchase Agreement.
🚩 Red Flags
- Immediate $13 million cash outflow triggered by the regulatory milestone.
📋 Key Facts
- FDA 510(k) clearance granted for the Simeox 200 device on December 30, 2024.
- The Simeox 200 is intended to promote airway clearance and improve bronchial drainage.
- A $13 million cash earnout milestone payment (Physio-Assist Milestone Payment) is now due.
- Payment must be made to the Sellers within ten business days of the FDA clearance date.
- The obligation stems from a Share Purchase Agreement dated July 10, 2023.
Inogen, Inc. filed an 8-K to furnish its third quarter 2024 financial results (ended September 30, 2024) via a press release.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The filing includes Exhibit 99.1 containing the quarterly earnings press release.
Inogen, Inc. filed an 8-K to furnish its second quarter 2024 financial results via a press release. This is a routine earnings announcement filing.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Second quarter ended June 30, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
Inogen, Inc. announced the execution of a transition agreement and release with Jason Somer, who departed from his role as Executive Vice President, General Counsel, and Secretary on July 19, 2024.
🚩 Red Flags
- Departure of a key executive (General Counsel/Secretary) can create temporary legal and administrative gaps.
📋 Key Facts
- Jason Somer's separation date was July 19, 2024.
- Mr. Somer served as EVP, General Counsel, and Secretary.
- A Transition Agreement and Release was entered into on July 26, 2024.
- Severance benefits will be provided consistent with his original employment agreement dated July 12, 2021.
Inogen, Inc. announced the mutual separation of Executive Vice President, General Counsel, and Secretary Jason Somer, effective July 19, 2024. The company simultaneously appointed Kevin P. Smith to succeed him in a combined role covering Business Development, Legal, and Corporate Secretary functions.
🚩 Red Flags
- Executive turnover involving the General Counsel/Secretary role can sometimes signal internal friction, though this filing characterizes it as 'mutual'.
📋 Key Facts
- Jason Somer will separate from the Company on July 19, 2024.
- Kevin P. Smith appointed as EVP, Business Development, General Counsel, and Secretary, effective July 22, 2024.
- Mr. Smith's compensation includes a $420,000 base salary, 50% target bonus, $100,000 sign-on bonus (subject to clawback), and $500,000 in RSUs vesting over three years.
- The separation of Mr. Somer is described as a mutual determination.
Inogen, Inc. reported the results of its 2024 annual meeting of stockholders held on June 5, 2024. Key outcomes included the approval of an amended equity incentive plan and the ratification of Deloitte & Touche LLP as the independent auditor.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Stockholders approved the Amended and Restated 2023 Equity Incentive Plan, which increases available shares by 1,200,000 and removes 'liberal' share counting rules.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- The Annual Meeting saw a quorum of approximately 81.95% (19,298,098 shares represented out of 23,546,871 outstanding).
- Elizabeth Mora and Heather Rider were elected to the Board as Class I directors.
- Shareholders provided an advisory 'for' vote on executive compensation.
Inogen, Inc. announced the execution of a separation agreement with Dr. Stanislav Glezer, who served as Executive Vice President, R&D and Chief Medical Officer. The departure was mutually determined and effective as of April 11, 2024.
🚩 Red Flags
- Departure of a high-level executive (EVP and Chief Medical Officer) can impact R&D leadership and clinical strategy.
📋 Key Facts
- Dr. Stanislav Glezer's role as an officer/employee ended effective April 11, 2024.
- The separation agreement was entered into on May 13, 2024.
- Severance benefits will be provided consistent with the existing Amended and Restated Employment and Severance Agreement dated October 11, 2021.
- The departure was previously announced in an 8-K filed on April 11, 2024.
Inogen, Inc. filed an 8-K to furnish its quarterly press release regarding financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 7, 2024
- Period covered: First quarter ended March 31, 2024
- The filing is primarily a placeholder to furnish Exhibit 99.1 (Press Release) per Item 2.02.
- Signed by Michael Bourque, CFO.
Inogen, Inc. announced the mutual separation of Dr. Stanislav Glezer from his roles as Executive Vice President, R&D and Chief Medical Officer, effective on or before May 3, 2024.
🚩 Red Flags
- Loss of key executive leadership (EVP of R&D and Chief Medical Officer) which may impact product development pipelines.
📋 Key Facts
- Dr. Stanislav Glezer is separating from the Company on or before May 3, 2024.
- The departure was a mutual determination between the Company and Dr. Glezer.
- The separation will involve a Separation Agreement with benefits consistent with his October 11, 2021, employment agreement.
- Material terms of the separation agreement will be disclosed in a future SEC filing.
Inogen, Inc. filed an 8-K to furnish its financial results for the fourth quarter and full fiscal year ended December 31, 2023. The filing serves as a formal announcement of quarterly earnings via press release.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Filing date: February 27, 2024.
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Inogen Inc. announced the appointment of Michael Bourque as Executive Vice President, Chief Financial Officer and Treasurer, effective March 4, 2024. This marks a transition from interim CFO Michael Sergesketter to a permanent successor.
🚩 Red Flags
- None identified; this is a standard executive succession filing.
📋 Key Facts
- Michael Bourque appointed as CFO/Treasurer effective March 4, 2024.
- Bourque's compensation includes a $425,000 annual base salary and a 60% target performance bonus.
- Sign-on bonus of $100,000 (repayable if terminated for cause or resignation within two years).
- Equity package includes up to 150,000 RSUs/PSUs (75k time-based, 75k performance-based).
- Interim CFO Michael Sergesketter will remain with the company to assist with the transition but will no longer be an executive officer.
- Severance includes 12 months of salary (or 24 months in a change of control scenario) plus COBRA benefits.
Inogen, Inc. announced the appointment of Grégoire Ramade as Chief Commercial Officer (CCO), effective January 2, 2024. Mr. Ramade transitions from his role as Senior Vice President of International Sales to this executive position.
🚩 Red Flags
- Guaranteed bonus component for the first two quarters may represent a short-term financial liability regardless of performance.
📋 Key Facts
- Grégoire Ramade appointed as Chief Commercial Officer (CCO) effective Jan 2, 2024.
- Ramade previously served as SVP of International Sales at Inogen since November 2023.
- Compensation includes an annual base salary of €364,000 and a target performance bonus of up to 60% of base salary.
- Employment agreement includes a guaranteed quarterly target achievement (50% of gross annual base) for the first two quarters.
- Severance provisions include 24 months' salary in the event of termination without cause following a change of control, and 12 months otherwise.